Andolast
Alternative Names: CR 2039; DiazolastLatest Information Update: 04 Aug 2015
At a glance
- Originator Rottapharm
- Developer Rottapharm Madaus
- Class Antiallergics; Antiasthmatics; Benzamides; Small molecules; Tetrazoles
- Mechanism of Action Calcium-activated potassium channel openers; Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 04 Aug 2015 Phase-III development is ongoing in Allergic rhinitis, Asthma and Chronic obstructive pulmonary disease in Italy
- 23 Oct 2014 Phase III development is ongoing in Allergic rhinitis, Asthma and Chronic obstructive pulmonary disease in Italy
- 10 Oct 2014 Rottapharm Madaus has been acquired by Meda